« Back
Home /
Tofacitinib

Tofacitinib

Item no.	HY-40354-5mg
Manufacturer	MedChem Express
CASRN	477600-75-2
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.99
Citations	[1]Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8.\|[2]Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55.\|[3]LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64(11):3531-42.\|[4]Calama E, et al. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS. Pulm Pharmacol Ther. 2017 Apr;43:60-67. Acta Pharmacol Sin. 2024 Sep 30.\|Adv Sci (Weinh). 2024 Dec 11:e2407398.\|Adv Sci (Weinh). 2024 Dec 5:e2410360.\|Ann Rheum Dis. 2021 Sep;80(9):1201-1208.\|Ann Rheum Dis. 2024 Aug 20:ard-2024-226067.\|Arch Dermatol Res. 2020 Jul;312(5):337-352.\|Biochem Pharmacol. 2020 Aug;178:114103.\|Biochem Pharmacol. 2023 May 19;213:115618.\|Biomed Chromatogr. 2021 Feb 1;e5081.\|bioRxiv. 2020 Dec 9;2020.12.09.416586.\|bioRxiv. 2024 Jan 24.\|bioRxiv. 2024 Oct 23:2024.10.20.619300.\|bioRxiv. 2025 February 21.\|BMC Med. 2021 Oct 15;19(1):247.\|Cell Rep Med. 2024 Nov 23:101840.\|Cell Rep. 2020 Sep 15;32(11):108158.\|Cell Rep. 2024 Oct 11;43(10):114866.\|Cell Syst. 2018 Apr 25;6(4):424-443.e7.\|Chemrxiv. 2023 Aug 3.\|Chemrxiv. Aug 11, 2021.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Exp Cell Res. 2021 Feb 15;399(2):112482.\|Food Chem Toxicol. 2020 Dec;146:111835.\|Free Radic Biol Med. 2019 Aug 1;139:80-91.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Inflamm Bowel Dis. 2020 Feb 11;26(3):407-422.\|Inflammation. 2023 Jun 13.\|Iran J Immunol. 2024 Sep 25;21(3).\|iScience. 2021 Sep 25;24(10):103173.\|iScience. 2024 Dec 10;28(1):111563.\|J Allergy Clin Immunol. 2023 Dec 8:S0091-6749(23)02411-9.\|J Biochem Mol Toxicol. 2021 Jul 31;e22851.\|J Immunol. 2013 Oct 1;191(7):3568-77. \|J Pharmacol Exp Ther. 2019 Aug;370(2):137-147. \|medRxiv. 2024 Sep 28:2024.09.26.24314341.\|Mol Biol Rep. 2022 Dec 12.\|Mol Hum Reprod. 2021 Mar 24;27(4):gaab016.\|Nano Res. 2023 Apr 15.\|Nat Commun. 2024 May 21;15(1):4327.\|Patent. US20180263995A1.\|Patent. US20220274992A1.\|Phytomedicine. November 2022, 154416.\|Phytother Res. 2021 Feb;35(2):1033-1047.\|PLoS One. 2018 Jan 10;13(1):e0189247. \|Pulm Pharmacol Ther. 2017 Apr;43:60-67. \|Research Square Preprint. 2024 Apr 19.\|Research Square Print. 2022 Aug.\|Research Square Print. 2023 Mar 14.\|Research Square Print. January 9th, 2023.\|Respir Res. 2022 Sep 13;23(1):244.\|Sci Adv. 2024 Mar 22;10(12):eadl0368.\|Sci Rep. 2021 Apr 1;11(1):7372.\|Sci Rep. 2022 May 12;12(1):7843.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Virulence. 2024 Jan 3:2301242.\|Cell Mol Gastroenterol Hepatol. 2021 Oct 6;S2352-345X(21)00192-2.\|Cell Prolif. 2021 Jan;54(1):e12933.\|Eur J Pharm Sci. 2024 Jul 4:106845.\|Int J Rheum Dis. 2020 Aug;23(8):1066-1075.\|J Med Chem. 2021 Feb 11.\|Pharmaceuticals. 2024 Jan 8, 17(1), 77.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Stem Cell Res Ther. 2024 Jun 18;15(1):177.
Smiles	O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Tasocitinib,CP-690550
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Apoptosis; JAK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	312.37
Product Description	Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
Manufacturer - Research Area	Inflammation/Immunology; Cancer
Solubility	DMSO: 125 mg/mL (ultrasonic)\|Ethanol: 2.5 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Isoform	JAK1; JAK2; JAK3
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-40354-5mg-safety-datasheet.pdf